Loading
A target and an antibody format: whether the Fc is engineered to recruit killer cells, silenced to avoid them, fused to a trap, or copied as a biosimilar. The grid below is target against antibody format: 49 by 6 from 119 medicines, 34 combinations approved, 40 in development, 3 tried and stopped, 249 untried in this corpus.
An enzyme blocker meant to stop tumours starving T cells of tryptophan. Its 2018 phase 3 failure ended an entire class overnight.
The first 'don't eat me' signal blocker. Gilead paid $4.9B for it; it was stopped in 2024 after trials showed more deaths, not fewer.
An immune-brake blocker that looked excellent in a phase 2 lung cancer trial and then failed every phase 3.
Primary PFS endpoint not met; numerical +5.1 months median PFS at the high dose.
Fianlimab + cemiplimab phase 3 (first-line melanoma): phase 3, negative · trial record
Terminated for futility after 77 of a planned 176 patients; no difference between arms on the interim analysis, per the registry; no publication (ClinicalTrials.gov NCT04447235).
Ivermectin plus losartan for COVID-19 in cancer patients (ICESP phase 2, terminated): phase 2, negative · trial record
Zumrad with BCG for BCG-naive high-risk non-muscle-invasive bladder cancer: marketing authorisation application withdrawn by Pfizer 13 Feb 2026 before a CHMP opinion, after the CHMP questioned protocol and statistical changes made during the main study
EMA / European Commission (EU): withdrawn · regulator row
MabCampath authorised 6 Jul 2001; marketing authorisation withdrawn at Genzyme's request 8 Aug 2012 (commercial reasons); patient access programmes continued nationally
EMA / European Commission (EU): withdrawn 2012 · regulator row
Withdrawn: the indication came off the label 4.9 years after its accelerated approval.
Genentech withdrew the US TNBC indication after the confirmatory IMpassion131 trial (paclitaxel partner) showed no progression-free or overall survival benefit and the FDA's accelerated-approval review; the current Tecentriq label carries no breast cancer indication
TNBC indication withdrawn after IMpassion131
Withdrawn: the indication came off the label 2.6 years after its accelerated approval.
Withdrawn: the indication came off the label 5.6 years after its accelerated approval.
iDFS HR 1.11 (0.87 to 1.42), p 0.38; stopped for futility at 2,199 of 2,300 patients.
ALEXANDRA / IMpassion030: phase 3, negative · trial record
PFS HR 1.03; OS HR 0.94, negative.
CONTACT-03: phase 3, negative · trial record
EFS HR 0.80 (0.62 to 1.03), p 0.083, not significant; OS HR 0.86 (0.62 to 1.19).
GeparDouze / NSABP B-59: phase 3, negative · trial record
Overall survival not improved: stratified hazard ratio 1.12 (95 percent confidence interval 0.91 to 1.37, p=0.28) for atezolizumab with enzalutamide against enzalutamide alone.
IMbassador250: phase 3, negative · trial record
Median overall survival 8.87 months with atezolizumab and cobimetinib against 8.51 months with regorafenib (hazard ratio 1.00).
IMblaze370: phase 3, negative · trial record
Interim RFS HR 0.72; benefit not sustained at update.
IMbrave050: phase 3, negative · trial record
PFS HR 0.82 (not significant); OS trend unfavourable; US indication withdrawn 2021.
IMpassion131: phase 3, negative · trial record
pCR 48.6% vs 44.4% (OR 1.18, p 0.48), not significant; EFS (primary) awaited.
NeoTRIP (NeoTRIPaPDL1): phase 3, negative · trial record
Withdrawn: the indication came off the label 3.7 years after its accelerated approval.
Median overall survival 22.6 against 21.5 months (hazard ratio 0.91, 95 percent confidence interval 0.78 to 1.05, p=0.181) despite progression-free survival 9.9 against 7.5 months and response 49.4 against 35.5 percent; treatment-related deaths 4.0 against 1.2 percent.
CALGB 90401: phase 3, negative · trial record
Bevacizumab added to radiotherapy and temozolomide did not improve event-free survival in newly diagnosed paediatric high-grade glioma.
HERBY: phase 2, negative · trial record
Bevacizumab added to radiotherapy and temozolomide prolonged progression-free survival but not overall survival in newly diagnosed glioblastoma.
AVAglio: phase 3, negative · trial record
OS 9.8 vs 10.0 months, HR 1.04 (95% CI 0.83-1.30); no benefit.
CheckMate 143: phase 3, negative · trial record
Complete response letter for camrelizumab + rivoceranib in HCC (manufacturing/inspection)
Second complete response letter
First CRL: manufacturing inspection findings
Second CRL
Third CRL, again cGMP
Primary PFS endpoint not met; numerical +5.1 months median PFS at the high dose.
Fianlimab + cemiplimab phase 3 (first-line melanoma): phase 3, negative · trial record
Three-year disease-free survival 71.5 with cetuximab against 74.6 percent without, in KRAS wild-type disease.
Alliance N0147: phase 3, negative · trial record
Severe toxicity similar; 2-year overall survival 97.5% (cisplatin) vs 89.4% (cetuximab).
De-ESCALaTE HPV: phase 3, negative · trial record
No overall survival gain from adding cetuximab to oxaliplatin-based first-line chemotherapy, including in KRAS wild-type disease.
MRC COIN: phase 3, negative · trial record
Median overall survival 55.4 months with cetuximab against 81.0 months without (hazard ratio 1.45).
New EPOC: phase 3, negative · trial record
No disease-free survival benefit from cetuximab in KRAS wild-type disease (hazard ratio 1.05).
PETACC-8: phase 3, negative · trial record
Median overall survival 28.7 months (60 Gy) vs 20.3 months (74 Gy); cetuximab no benefit.
RTOG 0617: phase 3, negative · trial record
5-year overall survival 84.6% (cisplatin) vs 77.9% (cetuximab); non-inferiority not met.
RTOG 1016: phase 3, negative · trial record
Complete response letter citing third-party manufacturing inspection findings
Withdrawn: the indication came off the label 3.8 years after its accelerated approval.
Durvalumab added to chemoradiotherapy did not significantly improve progression-free survival in locally advanced cervical cancer.
CALLA: phase 3, negative · trial record
Stopped early; primary endpoint not met.
DREAM3R: phase 3, negative · trial record
Concurrent durvalumab with chemoradiotherapy did not significantly improve progression-free survival over chemoradiotherapy alone.
PACIFIC-2: phase 3, negative · trial record
Median overall survival 11.2 against 10.0 months (hazard ratio 0.85, 95 percent confidence interval 0.72 to 1.00, p=0.053), missing significance; hazard ratio 1.46 in the first 5 months and 0.60 beyond 12 months. Grade 3 to 4 immune-related adverse events 26 against 3 percent, with four treatment-related deaths.
CA184-043: phase 3, negative · trial record
Nivolumab plus low-dose ipilimumab did not improve recurrence-free survival over nivolumab alone after resection of stage III to IV melanoma.
CheckMate 915: phase 3, negative · trial record
Nivolumab plus ipilimumab did not improve survival over nivolumab alone; the trial closed for futility.
Lung-MAP S1400I: nivolumab with or without ipilimumab: phase 3, negative · trial record
MAA withdrawn 2022
EMA / European Commission (EU): withdrawn 2022 · regulator row
Portrazza authorised 15 Feb 2016; Lilly did not apply for renewal and the authorisation expired 18 Feb 2021 (lack of demand)
EMA / European Commission (EU): withdrawn 2021 · regulator row
Theraloc (Oncoscience AG): marketing authorisation application withdrawn before a Commission decision. EMA register: 'Application withdrawn: The application for this medicine has been withdrawn'; checked 2026-09-24
EMA / European Commission (EU): withdrawn · regulator row
Withdrawn: the indication came off the label 2.4 years after its accelerated approval.
Withdrawn: the indication came off the label 3.8 years after its accelerated approval.
Median progression-free survival 4.2 against 5.9 months (hazard ratio 1.15, p=0.25) and overall survival 14.4 against 13.2 months (hazard ratio 1.02): the primary endpoint was not met.
CheckMate 026: phase 3, negative · trial record
OS 9.8 vs 10.0 months, HR 1.04 (95% CI 0.83-1.30); no benefit.
CheckMate 143: phase 3, negative · trial record
OS 13.4 vs 14.9 months, HR 1.31 (95% CI 1.09-1.58); worse with nivolumab.
CheckMate 498: phase 3, negative · trial record
OS 28.9 vs 32.1 months, HR 1.1 (95% CI 0.9-1.3); no PFS or OS benefit.
CheckMate 548: phase 3, negative · trial record
Nivolumab plus low-dose ipilimumab did not improve recurrence-free survival over nivolumab alone after resection of stage III to IV melanoma.
CheckMate 915: phase 3, negative · trial record
Nivolumab plus ipilimumab did not improve survival over nivolumab alone; the trial closed for futility.
Lung-MAP S1400I: nivolumab with or without ipilimumab: phase 3, negative · trial record
RFS not improved.
RELATIVITY-098: phase 3, negative · trial record
PFS HR 1.10; no benefit from nivolumab rechallenge.
TiNivo-2: phase 3, negative · trial record
Progression-free survival hazard ratio 0.92 (p = 0.39): no benefit over rituximab, with more grade 3 to 5 and fatal adverse events.
GOYA: phase 3, negative · trial record
Arzerra authorised 19 Apr 2010; marketing authorisation withdrawn at Novartis's request 28 Feb 2019 (commercial reasons)
EMA / European Commission (EU): withdrawn 2019 · regulator row
Withdrawn: the indication came off the label 1.8 years after its accelerated approval.
Withdrawn: the indication came off the label 4.4 years after its accelerated approval.
iDFS HR 1.11 (0.87 to 1.42), p 0.38; stopped for futility at 2,199 of 2,300 patients.
ALEXANDRA / IMpassion030: phase 3, negative · trial record
Primary PFS endpoint not met; numerical +5.1 months median PFS at the high dose.
Fianlimab + cemiplimab phase 3 (first-line melanoma): phase 3, negative · trial record
PFS HR 0.82 (not significant); OS trend unfavourable; US indication withdrawn 2021.
IMpassion131: phase 3, negative · trial record
OS in CPS 10 or more 12.7 vs 11.6 months (HR 0.78, p 0.057); CPS 1 or more 10.7 vs 10.2 (HR 0.86); all patients 9.9 vs 10.8 (HR 0.97). Negative.
KEYNOTE-119: phase 3, negative · trial record
Pembrolizumab added to chemoradiotherapy did not significantly improve event-free survival.
KEYNOTE-412: phase 3, negative · trial record
Median overall survival 24.7 against 27.3 months (hazard ratio 1.04, 95 percent confidence interval 0.88 to 1.22) and radiographic progression-free survival 10.4 against 9.0 months (0.98, 0.84 to 1.14); stopped for futility. Grade 3 or higher treatment-related adverse events 31.2 against 10.8 percent.
KEYNOTE-641: phase 3, negative · trial record
Median radiographic progression-free survival 8.6 against 8.3 months (hazard ratio 0.85, 95 percent confidence interval 0.71 to 1.01) and overall survival 19.6 against 19.0 months (0.92, 0.78 to 1.09); neither endpoint met.
KEYNOTE-921: phase 3, negative · trial record
Radiographic progression-free survival hazard ratio 1.20 (95 percent confidence interval 0.96 to 1.49, p=0.9467), medians not reached; stopped for futility. Grade 3 or higher adverse events 61.9 against 38.1 percent and rash 25.1 against 9.3 percent.
KEYNOTE-991: phase 3, negative · trial record
OS HR 0.84, not significant.
LEAP-002: phase 3, negative · trial record
Primary endpoint not met (ASCO GU 2026).
LITESPARK-012: phase 3, negative · trial record
Genmab has decided to discontinue further clinical development of acasunlimab following strategic portfolio prioritization. The decision was not related to safety concerns.
Pathological complete response 44.4% (T-DM1 + pertuzumab) vs 55.7% (TCHP); more locoregional progression before surgery with T-DM1.
KRISTINE: phase 3, negative · trial record
RFS not improved.
RELATIVITY-098: phase 3, negative · trial record
No difference in progression-free survival (hazard ratio 0.93) or overall survival (1.09) against R-CHOP, with substantially more febrile neutropenia, mucositis and neuropathy.
Alliance/CALGB 50303: phase 3, negative · trial record
Progression-free survival hazard ratio 0.92 (p = 0.39): no benefit over rituximab, with more grade 3 to 5 and fatal adverse events.
GOYA: phase 3, negative · trial record
CRL Mar 2022 for ORIENT-11 (single-country trial); ODAC 14 to 1
FDA (US): rejected 2022 · regulator row
Complete response letter for ORIENT-11 (first-line non-squamous NSCLC); ODAC voted 14 to 1 that additional data were needed for US applicability
Pathological complete response 44.4% (T-DM1 + pertuzumab) vs 55.7% (TCHP); more locoregional progression before surgery with T-DM1.
KRISTINE: phase 3, negative · trial record
These medicines belong to the format but their target is on no record the engine reads: the targets field is empty, the target lists no such drug, the trials linked to it name no target of its own, and the modality, mechanism and summary text name none the corpus knows. They are listed here rather than placed by guesswork; adding the target to the record puts them in the grid on the next build.
Each medicine's parts come from its own record: the targets field first, else the target records that list the medicine, else a sibling conjugate that shares its antibody name, else the trials linked to it, else the target names the corpus knows found in its modality, mechanism or summary text. The second part is read from the medicine's technology links first and from its modality and mechanism text second; a part no record names is shown as not recorded. Every part carries the fields it was read from and a confidence in the JSON file.
Approved: a medicine in the cell has an approval row or a regulator's approved entry and is not recorded as withdrawn. In development: a recruiting, active or planned trial, a development-phase record status, or active studies in the ClinicalTrials.gov index, and no approval. Tried and stopped: every medicine in the cell is withdrawn, negative or historic, or its only trial evidence is a terminated, withdrawn or negative study, or its approval was withdrawn. Untried: no medicine in this corpus combines the two parts.
A cell is coloured by its strongest medicine; the table shows each medicine with its own state. The reasons quoted under Stopped, and why are the records' words, including the registry's whyStopped text where the sponsor wrote one, and include stopped studies of medicines that are still in development elsewhere. Nothing here is medical advice.